Archives

by in
Entry Author Date Location
Starting a Company Is Hard. Good Health Insurance Makes It Easier. 08/30/13 Boston
Syndax Pockets $26.6M For Final Stage Push With Cancer Drug 08/27/13 Boston
East Coast Life Sciences Roundup: Mana, Medivizor, Regado, & More 08/23/13 New York
Join Us, and Boston’s “Life Science Disruptors,” on Oct. 2 08/21/13 Boston
Adimab Teams Up With Celgene, Innovent, in Latest Partnership Deals 08/20/13 Boston
East Coast Life Sciences Roundup: Epizyme, Rodin, Ophthotech, & More 08/16/13 Boston
Epizyme Execs Share the Secret to a Successful IPO: PowerBars 08/15/13 Boston
East Coast Life Sciences Roundup: KiiLN, Celgene, Acceleron, & More 08/09/13 New York
Celgene Partner Acceleron Files For IPO; Plans to Raise Up to $75M 08/07/13 Boston
Celgene Emerges as Biotech’s Shrewdest, Nimblest Dealmaker 08/05/13 National
East Coast Biotech Roundup: Cubist, Acetylon, Foundation, & More 08/02/13 Boston
Foundation Medicine Lays Groundwork For $86M IPO 07/29/13 Boston
Array to Receive $11M From Celgene as Part of New Development Deal 07/29/13 Boulder/Denver
Celgene Nabs Option to Buy Acetylon for More Than $1.7B 07/29/13 Boston
Agios Rockets to $29 Per Share in Market Debut 07/24/13 Boston
Agios Prices Upsized IPO Above Range, Preps For Nasdaq Debut 07/24/13 Boston
The Biotech IPO Phenomenon of 2013: Enjoy It While It Lasts 07/22/13 National
East Coast Life Sciences Roundup: Celgene, Dunsire, Forma, & More 07/12/13 Boston
Trusting Your Partners: A Chat With Celgene’s George Golumbeski 07/11/13 New York
Forma, CRT Deal Part of Broader Research Initiative 07/09/13 Boston
East Coast Life Sciences Roundup: Verdine, Vedanta, Alnylam, & More 07/05/13 Boston
Sunesis Waits Out Suspenseful Final Year of Pivotal Leukemia Trial 07/02/13 San Francisco
East Coast Life Sciences Roundup: J&J, Celgene, Zafgen, & More 06/28/13 Boston
Bluebird Prices Ahead of Range, Takes Flight on Nasdaq Today 06/19/13 Boston
East Coast Life Sciences Roundup: Agios, Ludwig/CRI, Celgene 06/14/13 Boston
Agios Files For IPO With Plans to Raise $86M 06/11/13 Boston
Profiles in Long-Termism: Sarepta Therapeutics CEO Chris Garabedian 06/10/13 National
East Coast Life Sciences Roundup: ASCO, Follica, Aveo, & More 06/07/13 Boston
Epizyme Soars 50 Percent in IPO Debut 05/31/13 Boston
Epizyme Prices IPO at $15 Per Share, Begins Trading Friday 05/30/13 Boston
Page 3 of 7 « previous page · next page »